$ATHX can rise in the next daysContextual immersion trading strategy idea.
Athersys is a biotechnology company, focuses on the research and development activities in the field of regenerative medicine.
The share price rose after good earnings. I see some preconditions the share price will continue growing.
The demand for shares of the company still looks higher than the supply.
These and other conditions can cause a rise in the share price in the next days.
So I opened a long position from $2,85;
stop-loss — $2,57.
Information about take-profits will be later.
Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision.
Always do your own analysis before making deals. When you use any materials, do not rely on blind trust.
You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy.
If you like my content, you can subscribe to the news and receive my fresh ideas.
Thanks for being with me!
Biotechstocks
$NBSE can rise in the next daysContextual immersion trading strategy idea.
NeuBase Therapeutics is a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes.
The demand for shares of the company looks higher than the supply.
These and other conditions can cause a rise in the share price in the next days.
So I opened a long position from $8,13;
stop-loss — $7,60.
Information about take-profits will be later.
Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision.
Always do your own analysis before making deals. When you use any materials, do not rely on blind trust.
You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy.
If you like my content, you can subscribe to the news and receive my fresh ideas.
Thanks for being with me!
$IFRX can rise in the next daysContextual immersion trading strategy idea.
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in the United States and Europe.
The share price rose after good earnings. I see some preconditions the share price will continue growing.
The demand for shares of the company still looks higher than the supply.
These and other conditions can cause a rise in the share price in the next days.
So I opened a long position from $7,22;
stop-loss — $6,73.
Information about take-profits will be later.
Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision.
Always do your own analysis before making deals. When you use any materials, do not rely on blind trust.
You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy.
If you like my content, you can subscribe to the news and receive my fresh ideas.
Thanks for being with me!
Nasdaq Healthcare: Closing on January 17thFriday's session presented a retracement on the 20 EMA Line, as predicted. I still believe in the continuation of the bullish trend. However, the bearish divergence needs to be monitored, since further price correction could occur.
Disclosure: My ideas contain statements and projections based on assumptions on capital markets, and therefore inherently subject to numerous risks and uncertainties.
Before buying or selling any stock you should do your own research and reach your own conclusion or consult a financial advisor. Investing includes risks, including loss of principal.
I am not a financial advisor
Healthcare: Closing on January 14thGood session for the Nasdaq Healthcare Index, that closed the day with a 1.30% gain. Bullish sentiment is still driving trades. However next session could be characterized by a retracement around the basis of the Bollinger Bands indicator (orange crosses).
This is a daily analysis.
Disclosure: My ideas contain statements and projections based on assumptions on capital markets, and therefore inherently subject to numerous risks and uncertainties.
Before buying or selling any stock you should do your own research and reach your own conclusion or consult a financial advisor. Investing includes risks, including loss of principal.
I am not a financial advisor
Alexion: Trading around Volume Profile POCIf you like this idea, don't forget to hit the Like Button!
Alexion business depends on patent-protected therapies in ultrarare and rare diseases of high unmet medical needs. While competitors are entering the market with biosimilars, Alexion still maintains an essential share of the market. My long term view is bullish.
However, from a technical point of view, we are in a critical consolidation phase that started at the end of October 2019. The stock price is consolidating around $107.88 level.
What to do now?
I would wait for Alexion to exit the consolidation phase with a breakout. My signal is the break of the $116.61 important resistance. Look at the purple line in the graph (Developing POC) to monitor interesting volumes movements able to push up the price (in the chart Developing POC is overlapping the POC red line). I suggest to not go in with a trade immediately after the resistance breakout since Alexion presents high uncertainty. Thus wait for a confirmation green candle (daily).
Disclosure: My ideas contain statements and projections based on assumptions on capital markets, and therefore inherently subject to numerous risks and uncertainties.
Before buying or selling any stock you should do your own research and reach your own conclusion or consult a financial advisor. Investing includes risks, including loss of principal.
I am not a financial advisor.
What's The Next Move For DARE?
Big news from Bayer and Dare today . Next thing to watch is for FDA approval and then if/when commercialization begins. Until then I think it's still very speculative. HOWEVER. important to note the chart. Last time it traded this high, it remained the case for a few weeks and then plummeted back down to earth. The last time it consistently traded around this price was way back in 2018. So could this mark a new, higher channel or another head fake?
"However, the fact remains that a commercialized drug in connection with a company like Bayer isn’t something to ignore. Dare could be entitled to as much as $310 million in milestone payments plus a tiered royalty structure. Does this make it one of the penny stocks to buy right now? That will be determined by the market reaction throughout the week, in my opinion. For now, at least, it seems like one of the penny stocks to watch to start the week."
Quote SOURCE: Best Penny Stocks To Watch This Week? 1 Up Over 210% This Year
DARE , OTC:BAYRY
Intuitive Surgical: expensive and to exit consolidationIntuitive Surgical produces robotic-assisted surgical systems. Currently, the company holds a significant market share in urology and gynecology areas. However, the business model is predicted to expand to other areas such as thoracic, colorectal, and other general soft tissue procedures.
From a technical point of view, the stock recovered the highs registered in April 2019, retracing on the last day of trading to the $581 level. However, the price was not able to overtake the $600 resistance that I consider essential in that case. The last session closed above the green Ichimoku Cloud; however, I see the price too close to the cloud support at $572.71.
An important signal comes from the Chikou Span (Lagging Span) of the Ichimoku Clouds. The "lagging span" is created by plotting closing prices 26 periods behind the latest closing price of an asset. Usually, when the price is above the line, it could be an indication of weakness (price too high). On the other hand, when the price is below the Chikou span, it could be an indication of strength (price too low). I highlighted in the graph the relationship between the Chikou Span and the current price. The last close perfectly matched the Lagging Span price.
Besides, I believe that the market overvalues the company. The stock is currently trading above its normal Price/EBITDA ratio of 32.75, at 50.13 (I used ten years of data). Probably the stock is too expensive.
My strategy is to wait until the green support of the green cloud (orange in the chart) is broken. To be sure of the beginning of a downtrend, however, wait until the red support of the green cloud is overtaken (purple in the chart).
Disclosure: My articles contain statements and projections based on assumptions on capital markets, and therefore inherently subject to numerous risks and uncertainties.
Before buying or selling any stock you should do your own research and reach your own conclusion or consult a financial advisor. Investing includes risks, including loss of principal.
I am not a financial advisor.
$LXRX Fill The Gap And Go Or Will It Breakdown?LXRX is a penny stock that has performed well over the last few weeks but looking at the chart, shares are trading within the gap zone. Volume this week compared to previous weeks is lower. Is that a concern or just a slow week?
"Shares of LXRX stock have been on a tear for around a month. This was ever since terminating its partnership agreement with Sanofi. The termination gave Lexicon full control over its diabetes product Zynquista and in addition to that, Sanofi is going to pay the company as much as $260 million as a parting shot...The company will be conducting poster presentations of its XERMELO therapy this week at the North American Neuroendocrine Tumor Society Annual Multidisciplinary NET Medical Symposium." *
About LXRX
Lexicon Pharmaceuticals is a biopharmaceutical company that uses mouse genetics to discover the function of genes and find promising drug targets. Lexicon then designs and develops drugs for these targets, which cover a broad spectrum of therapeutic areas. Following a restructuring in January 2014, Lexicon focused efforts on two drugs: sotagliflozin in diabetes, which is partnered with Sanofi, and Xermelo (telotristat etiprate) in carcinoid syndrome, which is partnered with Ipsen outside the U.S. Early-stage programs include SGLT1 inhibitor LX2761 and neuropathic pain drug LX9211.
*SOURCE: Are Penny Stocks Worth It? 3 Up Big In October
Did IGXT Just Give It All Back?IGXT traded almost the same share volume as previous on Monday with a big red candle. Does this signal weakness for the stock and will it be able to hold levels at or above the previous gap it had from months prior?
"The biotech penny stock 's price increased by 61.5% over the month. It started with the company presenting at the H.C Wainwright 21st Annual Global Investment Conference which occurred on September 9th. Towards the end of the month, IntelGenx announced its resubmission of RIZAPORT’s New Drug Application."*
Volume is always something to pay attention to especially when you talk about finding penny stocks to watch .
*Quote Source: 5 Money Making Penny Stocks To Watch This Week
Stock: IGXT
$SNNA Trying To Fill The Gap?The clinical-stage biopharmaceutical company ( SNNA ) enjoyed an incredible rally and skyrocketed by as much as 76% on Monday.
There was no material news with regards to the company that could have been a catalyst. It is perhaps more intriguing since on September 17 it had emerged that the company had filed for Chapter 11 bankruptcy. This was done in order to restructure the company. That being said, the recent rally makes things very interesting.
Source: 3 Penny Stocks To Buy or Sell In October?
Are New Highs In Store For CAPR?One of the penny stocks to watch due to its recent performance is that of Capricor Therapeutics Inc (CAPR Stock Report). Back on September 24, the company had been granted a meeting by the United States Food and Drug Administration.
" Shares gained as much as 20% as Capricor stock started the week with a bang. It is one of the biotech penny stocks that have performed impressively over recent days. Obviously with news like this and the type of momentum CAPR stock is seeing, many will have it on their watch lists for the week.
"
Source: 3 Penny Stocks To Buy or Sell In October?
Slow Churn Higher Or Another Pause For BLCM?"Since August 21st, Bellicum’s stock has made a very strong rally on the back of news releases. The price of the biotech penny stock is up nearly over 30% since the beginning of the month. This gain and volume increase came initially following the company’s $140 million public offering on the 21st. Bellicum is also participating in 3 healthcare investor conferences throughout September."
Source: A List Of Penny Stocks To Watch As They Approach September Highs
pennystocks.com
And I understand how speculation could play a role. However, there's less volume now compared to a few weeks ago and it's approaching a level that also falls in line with previous levels it was at before.
Can MRNS go the distance this week?"On Tuesday, the company earned attention from analysts at H.C. Wainwright. The research firm initiated coverage on MRNS stock. It gave the company a “BUY” rating as well as a price target of $5 per share. This was the 3rd analyst firm to initiate coverage on the stock this year. Previous to H.C. Wainwright, Jefferies and Leerink Swann both initiated coverage with “BUY” and “Outperform” ratings, respectively, for the penny stock. The two other firms also..."
3 Penny Stocks Making New Highs In September
NASDAQ:MRNS
$3 is Key Area SupportMake sure that $3 area holds and Volume stays consistent to keep driving these prices higher.
NTEC Jumped above $0.70 since falling apartWhat are the thoughts here? News? -NOPE...pure momentum today? Biggest volume it's had since the big drop day so what can explain this move?
"Intec Pharma Ltd. is a biotechnology company that creates drugs using its Accordion Pill technology. This technology is designed to improve the safety of drugs when taken orally. The company currently has 5 treatments in its pipeline with AP-CD/LD in Phase 3 trials.Over the last 2 trading sessions, Intec’s stock price has seen significant gains. On August 27th the stock price rose 14.8% and in premarket trading, on the 28th it has risen another 15%. These percentage gains allowed the biotech penny stock to go from $0.45 to $0.61."
Original Article: 4 Penny Stocks To Watch Under $4
NASDAQ:NTEC
